肺内皮は肺栓塞性血栓溶解をターゲットにしています
Bi-Sen Ding1, Ying-Jiang Zhou, Xin-Yuan Chen
1Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China.
Circulation
|November 12, 2003
まとめ
肺内皮を標的とする新型抗体-薬物結合剤は,肺栓塞の強力な血栓溶解を示しています. この標的療法により,血栓の溶解が促進され,出血合併症のリスクが著しく低下します.
科学分野:
- バイオメディカルエンジニアリング
- 血管生物学 血管生物学
- 薬理学 薬理学とは
背景:
- 肺栓塞 (PE) は,入院患者における一般的な,生命を脅かす状態です.
- PEの現在の血栓解消療法では,重度の出血合併症のリスクが高くなります.
- 肺内皮特異性抗体を活用した新しい治療法が開発されました.
研究 の 目的:
- 肺栓塞に対する標的型血栓解消療法を開発し,評価する.
- 肺内皮に特異的な抗体とウロキナーゼ結合体の有効性と安全性を評価する.
- 新規結合体と未結合ウロキナーゼを臨床前モデルで比較する.
主な方法:
- 肺血管内皮膜タンパク質の分離とモノクローナル抗体 (RE8F5) の開発.
- RE8F5抗体に対するウロキナーゼの結合.
- 肺,肝臓,下肢栓塞のラットモデルにおけるin vivo生物分布研究と血栓解離評価.
主要な成果:
- RE8F5抗体とそのウロキナーゼ結合体は,肺に迅速かつ特異的な蓄積を示した.
- ウロキナーゼ-RE8F5コンジュガートは,ウロキナーゼ単独と比較して,肺栓塞に対する血栓解消効力の12倍の増加を示した.
- コンジュガートは,フィブリノゲン濃度や出血時間に影響を及ぼさなかったが,ウロキナーゼとは異なり,フィブリノゲンの大量消費を引き起こした.
結論:
- 肺内皮に特異的な抗体と結合したウロキナーゼは,肺栓塞の有効で安全な治療法です.
- この標的型アプローチは,出血のリスクを最小限に抑えながら,高血栓解消効果を提供します.
- 抗体-薬物結合体は,全身性血栓解離と比較して,肺栓塞のモデルで優れたパフォーマンスを示しています.
関連する概念動画
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:29Pulmonary Embolism I: Introduction
1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749
01:27Pulmonary Embolism III: Nursing Management
756
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
756
01:19Pulmonary Embolism I: Introduction
39
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
39